ERAS (Erasca) Debt-to-Equity : 0.12 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Erasca Debt-to-Equity?

Erasca's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $4.45 Mil. Erasca's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $48.49 Mil. Erasca's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $450.04 Mil. Erasca's debt to equity for the quarter that ended in Sep. 2024 was 0.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Erasca's Debt-to-Equity or its related term are showing as below:

ERAS' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.27 Med: 0.12 Max: 0.19
Current: 0.12

During the past 5 years, the highest Debt-to-Equity Ratio of Erasca was 0.19. The lowest was -0.27. And the median was 0.12.

ERAS's Debt-to-Equity is ranked better than
54.03% of 1029 companies
in the Biotechnology industry
Industry Median: 0.15 vs ERAS: 0.12

Erasca Debt-to-Equity Historical Data

The historical data trend for Erasca's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Erasca Debt-to-Equity Chart

Erasca Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.27

-0.03

0.04

0.13

0.18

Erasca Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															0.17	0.18	0.19	0.12	0.12

Competitive Comparison of Erasca's Debt-to-Equity

For the Biotechnology subindustry, Erasca's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Erasca's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Erasca's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Erasca's Debt-to-Equity falls into.

Erasca Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Erasca's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.97	+	51.889)	/	316.686
	=	0.18

Erasca's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.45	+	48.489)	/	450.042
	=	0.12

Erasca (NAS:ERAS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Erasca Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Erasca's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Erasca Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Erasca Inc (NAS:ERAS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

3115 Merryfield Row, Suite 300, San Diego, CA, USA, 92121

Website

https://www.erasca.com

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Executives

Alexander W. Casdin	director	C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
Jonathan E Lim	director, 10 percent owner, officer: See Remarks	11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121
Start Valerie Denise Harding	director	C/O IGNYTA, INC., 11111 FLINTKOTE AVE., SAN DIEGO CA 92121
Shannon Morris	officer: Chief Medical Officer	C/O ERASCA, INC., 3115 MERRYFIELD ROW, SUITE 300, SAN DIEGO CA 92121
James Arthur Bristol	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Cormorant Asset Management, Lp	director	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp	director	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	director	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	director	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Jean I Liu	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Pratik S Multani	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Julie Hambleton	director	C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Ebun Garner	officer: General Counsel	C/O ALPHATEC HOLDINGS, INC., 2051 PALOMAR AIRPORT ROAD, CARLSBAD CA 92011
Arch Venture Partners X Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Lim Conyee T.	10 percent owner	C/O ERASCA, INC., 10835 ROAD TO THE CURE #140, SAN DIEGO CA 92121